^
Association details:
| Biomarker: | PPP2R2A mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Published date:
05/21/2020
Excerpt:
...Patients with PPP2RA mutations in the profound trial experienced an unfavorable risk benefit profile. Therefore olaparib is not recommended in patients with PPP2RA mutations.